By admin 
The fight against pediatric cancer has reached a pivotal juncture as CureSearch for Children’s Cancer, a leading national non-profit, announced the recipient of its prestigious 2026 Catapult Award. Dr. Robbie Majzner, a renowned physician-scientist at the Dana-Farber Cancer Institute, has been selected to receive a $2 million investment to spearhead a Phase I clinical trial for a next-generation immunotherapy targeting neuroblastoma. Co-funded by the Jeff Gordon Children’s Foundation, this initiative aims to address the critical survival gap for children and young adults diagnosed with relapsed or refractory forms of this aggressive solid tumor. The investment represents a strategic effort to move high-potential laboratory discoveries into the clinical setting, offering a new lifeline to patients who have exhausted standard treatment options.
The Clinical Challenge: Understanding High-Risk Neuroblastoma
Neuroblastoma is a complex cancer that develops from immature nerve cells, most commonly arising in the adrenal glands, but also appearing in the abdomen, chest, or neck. It remains the most frequently diagnosed extracranial solid tumor in childhood, accounting for approximately 7% to 10% of all pediatric cancer cases and more than 10% of childhood cancer-related deaths. In the United States alone, roughly 800 new cases are diagnosed annually, with the majority of patients being under the age of five.
Despite advancements in multi-modal therapy—which typically includes high-dose chemotherapy, surgical resection, radiation, and stem cell transplants—the prognosis for high-risk neuroblastoma remains sobering. For children with high-risk disease, the five-year survival rate is currently less than 50%. The primary obstacle in the field is the high rate of relapse; once the disease returns or becomes refractory (resistant to treatment), the medical community lacks a standardized, effective cure. Furthermore, survivors of current intensive treatments often face lifelong health complications, including hearing loss, cardiac issues, and secondary malignancies, underscoring the urgent need for targeted therapies that are both more effective and less toxic.
The Evolution of CAR T-Cell Therapy and the Solid Tumor Barrier
Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of hematologic malignancies, such as B-cell acute lymphoblastic leukemia (ALL) and certain lymphomas. This approach involves extracting a patient’s own T-cells—the "soldiers" of the immune system—and genetically engineering them to express receptors that recognize specific proteins on cancer cells. Once infused back into the patient, these modified cells seek out and destroy the malignancy.
However, translating this success to solid tumors like neuroblastoma has proven exceptionally difficult. Unlike blood cancers, solid tumors create a "hostile" microenvironment that suppresses immune activity. One of the most significant hurdles is T-cell exhaustion, a state where the engineered cells lose their ability to function and proliferate after initial contact with the tumor. In previous trials targeting GD2—a sugar-fat molecule (ganglioside) expressed on the surface of nearly all neuroblastoma cells—CAR T-cells often failed to persist long enough to eradicate the tumor entirely, leading to disease recurrence.
Technical Innovation: The ZAP70 Signaling Breakthrough
The research led by Dr. Robbie Majzner at Dana-Farber Cancer Institute addresses the exhaustion problem through a fundamental redesign of the CAR architecture. Traditional CAR T-cells rely on signaling domains like CD3-zeta to activate the T-cell upon binding to a target. Dr. Majzner’s team has replaced or augmented these traditional signals with a novel signaling protein known as ZAP70 (Zeta-chain-associated protein kinase 70).
In a healthy immune system, ZAP70 plays a critical role in T-cell receptor signaling, helping the body distinguish between persistent threats and normal cells. By incorporating ZAP70 into the CAR construct, the researchers have created a more "physiologic" signaling pathway. Preclinical data indicates that these redesigned cells are more resilient; they remain active longer, resist the molecular signals that trigger exhaustion, and maintain a sustained attack against GD2-expressing cancer cells. In laboratory models, this next-generation therapy demonstrated significantly stronger anti-tumor activity and improved persistence compared to the first-generation GD2-targeted therapies currently in use.
Strategic Funding: The CureSearch Catapult Award and the "Valley of Death"
The path from a successful laboratory experiment to a human clinical trial is often referred to by researchers as the "Valley of Death." This phase requires significant financial resources, regulatory navigation, and manufacturing infrastructure that traditional academic grants often do not cover. The CureSearch Catapult Award was specifically designed to bridge this gap.
By providing $2 million in funding, CureSearch and the Jeff Gordon Children’s Foundation are ensuring that Dr. Majzner’s work does not stall at the bench. This award focuses on "catapulting" research through the final stages of preclinical development and into Phase I trials, where the safety and preliminary efficacy of the therapy can be tested in patients. The involvement of the Jeff Gordon Children’s Foundation highlights a collaborative spirit in the philanthropic community, pooling resources to maximize the impact on pediatric oncology. Since its inception, CureSearch has been a vocal advocate for "bench-to-bedside" research, prioritizing projects with a clear and accelerated path to patient impact.
Chronology of Development and the 2026 Trial Roadmap
The timeline for this project reflects years of rigorous scientific inquiry. Following the initial discovery of the ZAP70 signaling advantages, Dr. Majzner’s team conducted extensive in vitro (cell culture) and in vivo (animal model) testing to validate the safety and potency of the construct. With the announcement of the 2026 Catapult Award, the project enters a critical implementation phase:
- 2024-2025: Finalization of manufacturing protocols. CAR T-cell therapy requires highly specialized "clean room" facilities to engineer patient cells. Researchers will work with Dana-Farber’s manufacturing centers to ensure the process is scalable and meets FDA standards.
- Late 2025: Submission of Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA). This process involves presenting all preclinical safety data to gain approval for human testing.
- 2026: Launch of the Phase I Clinical Trial. The trial will enroll children and young adults with relapsed or refractory neuroblastoma. The primary goal will be to assess the safety of the ZAP70-GD2 CAR T-cells and determine the optimal dosage.
- Ongoing Monitoring: Researchers will use advanced biomarkers to track the persistence of the T-cells in the patients’ blood and monitor for signs of tumor regression.
Official Responses and Institutional Support
The announcement has been met with optimism from the pediatric oncology community. Dr. Paisley Myers, Senior Director of Research & Programs at CureSearch, emphasized the organization’s mission-driven approach. "One of the greatest challenges in pediatric cancer research is ensuring that promising discoveries reach children," Dr. Myers stated. "Through the Catapult Award, CureSearch helps move innovative therapies from the laboratory into clinical trials. Dr. Majzner’s work exemplifies the bold, high-potential research we were created to support."
Dr. Robbie Majzner expressed the importance of this funding in overcoming the limitations of current immunotherapies. He noted that while previous GD2 CAR T-cells showed promise in patients with low disease burdens, they often failed in more advanced cases. "We’ve designed a brand-new CAR architecture that breaks past limitations to success in lab models," Majzner said. "The CureSearch Catapult Award is vital to our mission; it gives us the momentum to catapult this science out of the lab and directly to the forefront of patient care."
Dana-Farber Cancer Institute, where the trial will be centered, remains one of the world’s premier locations for pediatric cancer research. The institute’s infrastructure provides the necessary clinical expertise and patient access to ensure the trial is conducted with the highest scientific and ethical standards.
Broader Impact and Future Implications
The implications of Dr. Majzner’s research extend beyond neuroblastoma. The GD2 molecule is also expressed in other pediatric and adult malignancies, including osteosarcoma (a bone cancer), certain types of brain tumors (such as H3K27M-mutant diffuse intrinsic pontine glioma or DIPG), and some small-cell lung cancers in adults. If the ZAP70-modified CAR T-cells prove successful in neuroblastoma, the underlying technology could be adapted to treat a wide array of GD2-positive cancers.
Furthermore, the success of the ZAP70 signaling platform could provide a blueprint for overcoming T-cell exhaustion in other CAR T-cell therapies. By demonstrating that physiologic signaling can improve T-cell persistence, this research may influence how CAR T-cells are engineered for various solid tumors, including breast, pancreatic, and colorectal cancers, which have similarly resisted current immunotherapy approaches.
As the medical community moves toward the 2026 trial launch, the focus remains on the children for whom current treatments have failed. The Catapult Award serves as a testament to the power of targeted philanthropy and scientific innovation working in tandem to rewrite the prognosis for the most vulnerable cancer patients. By investing in the "momentum" of science, CureSearch and its partners are not just funding a study; they are fostering a potential paradigm shift in the treatment of childhood cancer.
